mDPR-Val-Cit-PAB-MMAE

• CAT Number: I001833
• CAS Number: 1491152-26-1
• Molecular Formula: C65H100N12O15
• Molecular Weight: 1289.56
• Purity: ≥95%
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: [4-[[(2S)-2-[[(2S)-2-[[(2S)-3-amino-2-(2,5-dioxopyrrol-1-yl)propanoyl]amino]-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
• InChI: InChI=1S/C65H100N12O15/c1-15-39(8)55(48(90-13)33-51(80)76-32-20-24-46(76)57(91-14)40(9)58(82)69-41(10)56(81)43-21-17-16-18-22-43)74(11)63(87)53(37(4)5)73-62(86)54(38(6)7)75(12)65(89)92-35-42-25-27-44(28-26-42)70-59(83)45(23-19-31-68-64(67)88)71-61(85)52(36(2)3)72-60(84)47(34-66)77-49(78)29-30-50(77)79/h16-18,21-22,25-30,36-41,45-48,52-57,81H,15,19-20,23-24,31-35,66H2,1-14H3,(H,69,82)(H,70,83)(H,71,85)(H,72,84)(H,73,86)(H3,67,68,88)/t39-,40+,41+,45-,46-,47-,48+,52-,53-,54-,55-,56+,57+/m0/s1
• InChIKey: QJDGTZXZKQAVTL-IIMIZLLVSA-N
• SMILES: CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CN)N4C(=O)C=CC4=O

mDPR-Val-Cit-PAB-MMAE（Cat No.:I001833） is an antibody-drug conjugate (ADC) comprising a linker called mDPR-Val-Cit-PAB and a potent tubulin inhibitor known as MMAE. The linker component, mDPR-Val-Cit-PAB, connects the antibody with the MMAE payload, ensuring selective delivery of the drug to target cells. MMAE acts as a potent tubulin inhibitor, disrupting microtubule dynamics and inhibiting cell division. By conjugating MMAE to the antibody via the linker, mDPR-Val-Cit-PAB-MMAE combines the targeting ability of the antibody with the cytotoxic effects of MMAE, enhancing its therapeutic potential in treating specific cancers and improving treatment outcomes.